The American Diabetes Association’s 85th Scientific Sessions is a leading forum for cutting-edge research, clinical advancements, and innovation in diabetes care. With sessions covering basic science, translational research, and clinical practice, this event brings together healthcare professionals, researchers, and industry leaders to drive progress in the prevention and treatment of diabetes.

This year, Dr. Steven Heymsfield will present efficacy and safety results from the BELIEVE Phase 2 study of bimagrumab + semaglutide—a trial CRO Consulting was proud to support—during the session "Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss While Preserving Lean Mass?" on Monday, June 23, from 8:00–9:30 a.m., in Room W375 A at McCormick Place Convention Center.